Are neuropeptides important in arthritis? Studies on the importance of bombesin/GRP and substance P in a murine arthritis model

Annals of the New York Academy of Sciences

Volumn 1110, Issue , 2007, Pages 525-538

  Grimsholm, O ^a   Guo, Yz ^a   Ny, T ^a   Rantapaa Dahlqvist S ^b   Forsgren, S ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Arthritis; Articular chondrocytes; Bombesin; GRP; Neurokinin 1 receptor; SP

Indexed keywords

BOMBESIN; GASTRIN RELEASING PEPTIDE; NEUROKININ 1 RECEPTOR; NEUROPEPTIDE; RECEPTOR PROTEIN; SUBSTANCE P; TACHYKININ RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CARTILAGE CELL; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATORY INFILTRATE; KNEE; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; STAINING;

MURINAE; MUS;

EID: 35748982434     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1423.056     Document Type: Conference Paper

References (55)

1. THOMPSON, M. & E.G. BYWATERS. 1962. Unilateral rheumatoid arthritis following hemiplegia. Ann. Rheum. Dis. 21: 370-377.
2. GLICK, E.N. 1967. Asymmetrical rheumatoid arthritis after poliomyelitis. Br. Med. J. 3: 26-28.
3. KANE, D. et al. 2005. Protective effect of sensory denervation in inflammatory arthritis (evidence of regulatory neuroimmune pathways in the arthritic joint). Ann. Rheum. Dis. 64: 325-327.
4. ANASTASI, A., V. ERSPAMER & M. BUCCI. 1971. Isolation and structure of bombesin and alytesin, 2 analogous active peptides from the skin of the European amphibians Bombina and Alytes. Experientia 27: 166-167.
5. OKUMA, Y., K. YOKOTANI & Y. OSUMI. 1995. Centrally applied bombesin increases nerve activity of both sympathetic and adrenal branch of the splanchnic nerves. Jpn. J. Pharmacol. 68: 227-230.
6. PERT, A. et al. 1980. Bombesin: receptor distribution in brain and effects on nociception and locomotor activity. Brain Res. 193: 209-220.
7. WESTERMARK, T. et al. 2001. Increased content of bombesin/GRP in human synovial fluid in early arthritis: different pattern compared with substance P. Clin. Exp. Rheumatol. 19: 715-720.
8. GRIMSHOLM, O., S. RANTAPAA-DAHLQVIST & S. FORSGREN. 2005. Levels of gastrin-releasing peptide and substance P in synovial fluid and serumcorrelate with levels of cytokines in rheumatoid arthritis. Arthritis Res. Ther. 7: R416-R426.
9. LOTZ, M., D.A. CARSON & J.H. VAUGHAN. 1987. Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science 235: 893-895.
10. SEEGERS, H.C. et al. 2003. Enhancement of angiogenesis by endogenous substance P release and neurokinin-1 receptors during neurogenic inflammation. J. Pharmacol. Exp. Ther. 306: 8-12.
11. KEEBLE, J.E. & S.D. BRAIN. 2004. A role for substance P in arthritis? Neurosci. Lett. 361: 176-179.
12. FOEY, A.D. et al. 2003. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis. Arthritis Res. Ther. 5: R317-R328.
13. LI, J. et al. 2005. Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models. Arthritis Rheum. 52: 2541-2548.
14. HANSSON, M. & S. FORSGREN. 1995. Immunoreactive atrial and brain natriuretic peptides are co-localized in Purkinje fibres but not in the innervation of the bovine heart conduction system. Histochem. J. 27: 222-230.
15. JONSSON, M., O. NORRGARD & S. FORSGREN. 2005. Substance P and the neurokinin-1 receptor in relation to eosinophilia in ulcerative colitis. Peptides 26: 799-814.
16. FORSGREN, S., P. DANIELSON & H. ALFREDSON. 2005. Vascular NK-1 receptor occurrence in normal and chronic painful Achilles and patellar tendons: studies on chemically unfixed as well as fixed specimens. Regul. Pept. 126: 173-181.
17. HILL, D.J. & T.J. MCDONALD. 1992. Mitogenic action of gastrin-releasing polypeptide on isolated epiphyseal growth plate chondrocytes from the ovine fetus. Endocrinology 130: 2811-2819.
18. MONTET, X., R. WEISSLEDER & L. JOSEPHSON. 2006. Imaging pancreatic cancer with a peptide-nanoparticle conjugate targeted to normal pancreas. Bioconjug. Chem. 17: 905-911.
19. CIMINI, V., S. VAN NOORDEN & J.M. POLAK. 1989. Co-localisation of substance P-, bombesin- and peptide histidine isoleucine (PHI)-like peptides in gut endocrine cells of the dogfish Scyliorhinus stellaris. Anat. Embryol. (Berl.) 179: 605-614.
20. MILLWARD-SADLER, S.J. et al. 2003. Tachykinin expression in cartilage and function in human articular chondrocyte mechanotransduction. Arthritis Rheum. 48: 146-156.
21. HERNANZ, A. et al. 1993. Calcitonin gene-related peptide II, substance P and vasoactive intestinal peptide in plasma and synovial fluid from patients with inflammatory joint disease. Br. J. Rheumatol. 32: 31-35.
22. ARNALICH, F. et al. 1994. Neuropeptides and interleukin-6 in human joint inflammation relationship between intraarticular substance P and interleukin-6 concentrations. Neurosci. Lett. 170: 251-254.
23. BUMA, P. et al. 2000. Neurovascular plasticity in the knee joint of an arthritic mouse model. Anat. Rec. 260: 51-61.
24. YEGEN, B.C. 2003. Bombesin-like peptides: candidates as diagnostic and therapeutic tools. Curr. Pharm. Des. 9: 1013-1022.
25. YAMAGUCHI, Y. et al. 2002. Gastrin-releasing peptide, a bombesin-like neuropeptide, promotes cutaneous wound healing. Dermatol Surg. 28: 314-9.
26. GULLUOGLU, B.M. et al. 1999. Bombesin ameliorates colonic damage in experimental colitis. Dig. Dis. Sci. 44: 1531-1538.
27. SAURIN, J.C. et al. 1999. Bombesin stimulates adhesion, spreading, lamellipodia formation, and proliferation in the human colon carcinoma Isreco1 cell line. Cancer Res. 59: 962-967.
28. CHU, K.U. et al. 1995. Bombesin stimulates mucosal growth in jejunal and ileal Thiry-Vella fistulas. Ann. Surg. 221: 602-609.
29. CUESTA, M.C. et al. 2002. Substance P and calcitonin gene-related peptide increase IL-1 beta, IL-6 and TNF alpha secretion from human peripheral blood mononuclear cells. Neurochem. Int. 40: 301-306.
30. LOTZ, M., J.H. VAUGHAN & D.A. CARSON. 1988. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science 241: 1218-1221.
31. HERNANZ, A. et al. 2003. Effect of calcitonin gene-related peptide, neuropeptide Y, substance P, and vasoactive intestinal peptide on interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha production by peripheral whole blood cells from rheumatoid arthritis and osteoarthritis patients. Regul. Pept. 115: 19-24.
32. KIM, W.K. et al. 2000. Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway. J. Neurosci. 20: 3622-3630.
33. GONZALEZ-REY, E. & M. DELGADO. 2005. Role of vasoactive intestinal peptide in inflammation and autoimmunity. Curr. Opin. Investig. Drugs 6: 1116-1123.
34. LAM, F.Y. & W.R. FERRELL. 1989. Inhibition of carrageenan induced inflammation in the rat knee joint by substance P antagonist. Ann. Rheum. Dis. 48: 928-32.
35. RUBENSTEIN, E.B. et al. 2006. New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 12: 341-7.
36. DE WIT, R. et al. 2004. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur. J. Cancer 40: 403-410.
37. KRAMER, M.S. et al. 1998. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281: 1640-1645.
38. HOLZER, P. 1998. Implications of tachykinins and calcitonin gene-related peptide in inflammatory bowel disease. Digestion 59: 269-283.
39. STUCCHI, A.F. et al. 2000. NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 279: G1298-G1306.
40. RIJNIERSE, A. et al. 2006. Beneficial effect of tachykinin NK1 receptor antagonism in the development of hapten-induced colitis in mice. Eur. J. Pharmacol. 548: 150-157.
41. WEINSTOCK, J.V. et al. 2003. Substance P regulates Th1-type colitis in IL-10 knockout mice. J. Immunol. 171: 3762-3767.
42. LUBER-NAROD, J. et al. 1997. Role of substance P in several models of bladder inflammation. Urol Res. 25: 395-399.
43. VAN DER KLEIJ, H.P. et al. 2003. Functional expression of neurokinin 1 receptors on mast cells induced by IL-4 and stem cell factor. J. Immunol. 171: 2074-2079.
44. CUMBERBATCH, M.J. et al. 1998. Reversal of behavioural and electrophysiological correlates of experimental peripheral neuropathy by the NK1 receptor antagonist GR205171 in rats. Neuropharmacology 37: 1535-1543.
45. WILLIAMS, R.O. 2002. Therapeutic effect of vasoactive intestinal peptide in collagen-induced arthritis. Arthritis Rheum. 46: 271-273.
46. DELGADO, M. et al. 2001. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat. Med. 7: 563-568.
47. DELGADO, M. & D. GANEA. 2003. Vasoactive intestinal peptide inhibits IL-8 production in human monocytes by downregulating nuclear factor kappaB-dependent transcriptional activity. Biochem. Biophys. Res. Commun. 302: 275-283.
48. GONZALEZ-REY, E. et al. 2006. Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis. Arthritis Rheum. 54: 864-876.
49. JUARRANZ, Y. et al. 2006. VIP decreases TLR4 expression induced by LPS and TNF-alpha treatment in human synovial fibroblasts. Ann. N. Y. Acad. Sci. 1070: 359-364.
50. JUARRANZ, Y. et al. 2005. Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res. Ther. 7: R1034-R1045.
51. JUARRANZ, M.G. et al. 2004.Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. Rheumatology (Oxf.) 43: 416-422.
52. GOMARIZ, R.P. et al. 2006. VIP-PACAP system in immunity: new insights for multitarget therapy. Ann. N. Y. Acad. Sci. 1070: 51-74.
53. BRAIN, S.D. 1997. Sensory neuropeptides: their role in inflammation and wound healing. Immunopharmacology 37: 133-152.
54. ACKERMANN, P.W., M. AHMED & A. KREICBERGS. 2002. Early nerve regeneration after achilles tendon rupture-a prerequisite for healing? A study in the rat. J. Orthop. Res. 20: 849-856.
55. NISHIDA, T. 2005. Neurotrophic mediators and corneal wound healing. Ocul. Surf. 3: 194-202.